Dapsone (oral)
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Dapsone (oral) is a anti infective agent that is FDA approved for the treatment of acne vulgar, dermatitis herpetiformis, leprosy. Common adverse reactions include nausea, vomiting, abdominal pain, pancreatitis, vertigo, blurred vision, tinnitus.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Indications
- Dermatitis herpetiformis
- Leprosy: All forms of leprosy except for cases of proven Dapsone resistance.
Dosage
Dermatitis herpetiformis: The dosage should be individually titrated starting in adults with 50 mg daily and correspondingly smaller doses in children. If full control is not achieved within the range of 50-300 mg daily, higher doses may be tried. Dosage should be reduced to a minimum maintenance level as soon as possible. In responsive patients there is a prompt reduction in pruritus followed by clearance of skin lesions. There is no effect on the gastrointestinal component of the disease. Dapsone levels are influenced by acetylation rates. Patients with high acetylation rates, or who are receiving treatment affecting acetylation may require an adjustment in dosage.
A strict gluten free diet is an option for the patient to elect, permitting many to reduce or eliminate the need for Dapsone; the average time for dosage reduction is 8 months with a range of 4 months to 2 1/2 years and for dosage elimination 29 months with a range of 6 months to 9 years.
Leprosy: In order to reduce secondary Dapsone resistance, the WHO Expert Committee on Leprosy and the USPHS at Carville, LA, recommended that Dapsone should be commenced in combination with one or more anti-leprosy drugs. In the multidrug program Dapsone should be maintained at the full dosage of 100 mg daily without interruption (with corresponding smaller doses for children) and provided to all patients who have sensitive organisms with new or recrudescent disease or who have not yet completed a two year course of Dapsone monotherapy. For advice and other drugs, the USPHS at Carville, LA (1-800-642-2477) should be contacted. Before using other drugs consult appropriate product labeling.
In bacteriologically negative tuberculoid and indeterminate disease, the recommendation is the coadministration of Dapsone 100 mg daily with six months of Rifampin 600 mg daily. Under WHO, daily Rifampin may be replaced by 600 mg Rifampin monthly, if supervised. The Dapsone is continued until all signs of clinical activity are controlled - usually after an additional six months. Then Dapsone should be continued for an additional three years for tuberculoid and indeterminate patients and for five years for borderline tuberculoid patients.
In lepromatous and borderline lepromatous patients, the recommendation is the co-administration of Dapsone 100 mg daily with two years of Rifampin 600 mg daily. Under WHO daily Rifampin may be replaced by 600 mg Rifampin monthly, if supervised. One may elect the concurrent administration of a third anti-leprosy drug, usually either Clofazamine 50-100 mg daily or Ethionamide 250-500 mg daily. Dapsone 100 mg daily is continued 3-10 years until all signs of clinical activity are controlled with skin scrapings and biopsies negative for one year. Dapsone should then be continued for an additional 10 years for borderline patients and for life for lepromatous patients.
Secondary Dapsone resistance should be suspected whenever a lepromatous or borderline lepromatous patient receiving Dapsone treatment relapses clinically and bacteriologically, solid staining bacilli being found in the smears taken from the new active lesions. If such cases show no response to regular and supervised Dapsone therapy within three to six months or good compliance for the past 3-6 months can be assured, Dapsone resistance should be considered confirmed clinically. Determination of drug sensitivity using the mouse footpad method is recommended and, after prior arrangement, is available without charge from the USPHS, Carville, LA. Patients with proven Dapsone resistance should be treated with other drugs.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Dapsone in adult patients.
Non–Guideline-Supported Use
Indications
- Cutaneous leishmaniasis
- Determination of acetylation rate
- Erythema elevatum diutinum
- HIV infection - Pneumocystis pneumonia
- HIV infection - Pneumocystis pneumonia; Prophylaxis
- HIV infection - Toxoplasmosis; Prophylaxis
- Lichen planus
- Malaria
- Pemphigoid
- Pemphigus
- Poisoning due to brown recluse spider venom
- Rheumatoid arthritis
- Thrombocytopenic purpura
Dosage
- HIV infection - Pneumocystis pneumonia: 100 mg ORALLY once daily, in combination with trimethoprim 15 mg/kg/day ORALLY in 3 divided doses for 21 days.
- HIV infection - Pneumocystis pneumonia; Prophylaxis: primary prophylaxis, 100 mg ORALLY once daily or 50 mg ORALLY twice daily; another alternative is dapsone 50 mg ORALLY once daily plus pyrimethamine 50 mg ORALLY and leucovorin 25 mg ORALLY once weekly.
- HIV infection - Pneumocystis pneumonia; Prophylaxis: secondary prophylaxis, 100 mg ORALLY once daily or 50 mg ORALLY twice daily; other alternatives include dapsone 50 mg ORALLY once daily plus pyrimethamine 50 mg ORALLY and leucovorin 25 mg ORALLY once weekly, or dapsone 200 mg ORALLY plus pyrimethamine 75 mg ORALLY plus leucovorin 25 mg once weekly.
- HIV infection - Toxoplasmosis; Prophylaxis: primary prophylaxis (alternative regimens), 50 mg ORALLY once daily plus pyrimethamine 50 mg ORALLY once weekly plus leucovorin 25 mg ORALLY once weekly, OR dapsone 200 mg plus pyrimethamine 75 mg plus leucovorin 25 mg ORALLY once weekly.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Indications
- Acne vulgaris
- Dermatitis herpetiformis
- Leprosy, in combination with other anti-leprosy medications
Dosing
- Acne vulgaris: (12 yr and older) TOPICALLY rub small amount into clean, dry, acne affected areas twice daily.
- Dermatitis herpetiformis: initial and maintenance dose schedule is the same as in adults, but given in correspondingly smaller doses.
- Leprosy, in combination with other anti-leprosy medications: 1 to 2 mg/kg ORALLY once a day, maximum 100 mg/day
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Dapsone in pediatric patients.
Non–Guideline-Supported Use
Indications
- HIV infection - Pneumocystis pneumonia; Prophylaxis
- HIV infection - Toxoplasmosis; Prophylaxis
Dosing
- HIV infection - Pneumocystis pneumonia; Prophylaxis: (1 month of age and older) primary and secondary prophylaxis, 2 mg/kg ORALLY once a day (MAX 100 mg/day); or 4 mg/kg ORALLY once weekly (MAX 200 mg/dose) .
- HIV infection - Toxoplasmosis; Prophylaxis: (1 month of age and older) primary prophylaxis, 2 mg/kg or 15 mg/m(2) (MAX 25 mg) ORALLY daily PLUS pyrimethamine 1 mg/kg (MAX 25 mg) ORALLY daily PLUS leucovorin 5 mg ORALLY every 3 days; continue leucovorin for 1 wk after pyrimethamine is stopped.
Contraindications
- Hypersensitivity to Dapsone and/or its derivatives.
Warnings
- The patient should be warned to respond to the presence of clinical signs such as sore throat, fever, pallor, purpura or jaundice. Deaths associated with the administration of Dapsone have been reported from agranulocytosis, aplastic anemia and other blood dyscrasias. Complete blood counts should be done frequently in patients receiving Dapsone. The FDA Dermatology Advisory Committee recommended that, when feasible, counts should be done weekly for the first month, monthly for six months and semi-annually thereafter. If a significant reduction in leucocytes, platelets or hemopoiesis is noted, Dapsone should be discontinued and the patient followed intensively. Folic acid antagonists have similar effects and may increase the incidence of hematologic reactions; if co-administered with Dapsone the patient should be monitored more frequently. Patients on weekly pyrimethamine and Dapsone have developed agranulocytosis during the second and third month of therapy.
- Severe anemia should be treated prior to initiation of therapy and hemoglobin monitored. Hemolysis and methemoglobin may be poorly tolerated by patients with severe cardiopulmonary disease.
- Cutaneous reactions, especially bullous, include exfoliative dermatitis and are probably one of the most serious, though rare, complications of sulfone therapy. They are directly due to drug sensitization. Such reactions include toxic erythema, erythema multiforme, toxic epidermal necrolysis, morbilliform and scarlatiniform reactions, urticaria and erythema nodosum. If new or toxic dermatologic reactions occur, sulfone therapy must be promptly discontinued and appropriate therapy instituted. Leprosy reactional states, including cutaneous, are not hypersensitivity reactions to Dapsone and do not require discontinuation. See special section.
Adverse Reactions
Clinical Trials Experience
In addition to the warnings listed above, the following syndromes and serious reactions have been reported in patients on Dapsone.
Hematologic Effects: Dose-related hemolysis is the most common adverse effect and is seen in patients with or without G6PD deficiency. Almost all patients demonstrate the inter-related changes of a loss of 1-2g of hemoglobin, an increase in the reticulocytes (2-12%), a shortened red cell life span and a rise in methemoglobin. G6PD deficient patients have greater responses.
Nervous System Effects: Peripheral neuropathy is a definite but unusual complication of dapsone therapy in non-leprosy patients. Motor loss is predominant. If muscle weakness appears, Dapsone should be withdrawn. Recovery on withdrawal is usually substantially complete. The mechanism of recovery is reported by axonal regeneration. Some recovered patients have tolerated retreatment at reduced dosage. In leprosy this complication may be difficult to distinguish from a leprosy reactional state.
Body As A Whole: In addition to the warnings and adverse effects reported above, additional adverse reactions include: nausea, vomiting, abdominal pains, pancreatitis, vertigo, blurred vision, tinnitus, insomnia, fever, headache, psychosis, phototoxicity, pulmonary eosinophilia, tachycardia, albuminuria, the nephrotic syndrome, hypoalbuminemia without proteinuria, renal papillary necrosis, male infertility, drug-induced Lupus erythematosus and an infectious mononucleosis-like syndrome. In general, with the exception of the complications of severe anoxia from overdosage (retinal and optic nerve damage, etc.) these adverse reactions have regressed off drug.
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Dapsone in the drug label.
Drug Interactions
- Rifampin lowers Dapsone levels 7 to 10-fold by accelerating plasma clearance; in leprosy this reduction has not required a change in dosage. Folic acid antagonists such as pyrimethamine may increase the likelihood of hematologic reactions.
- A modest interaction has been reported for patients receiving 100 mg Dapsone daily in combination with trimethoprim 5 mg/kg q6h. On Day 7, the serum Dapsone levels averaged 2.1 ± 1.0 μg/mL in comparison to 1.5 ± 0.5 μg/mL for Dapsone alone. On Day 7, trimethoprim levels averaged 18.4 ± 5.2 μg/mL in comparison to 12.4 ± 4.5 μg/mL for patients not receiving Dapsone. Thus, there is a mutual interaction between Dapsone and trimethoprim in which each raises the level of the other about 1.5 times.
- A crossover study1 designed to assess the potential of a drug interaction between Dapsone, 100 mg/day and trimethoprim, 200 mg every 12 hours, in eight asymptomatic HIV positive volunteers (average CD4 count 524 cells/mm3) demonstrated that there was not a significant drug intreraction between Dapsone and trimethoprim. However, an earlier report2 also by Lee et al, in 78 HIV infected patients with acute Pneumocystis carinii pneumonia, receiving Dapsone, 100 mg/day and higher trimethoprim dose, 20 mg/kg/day, demonstrated that the serum levels of Dapsone were increased by 40% and trimethoprim levels were increased by 48% when the drugs were administered concurrently.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
Pregnancy: Teratogenic Effects. Pregnancy Category C: Animal reproduction studies have not been conducted with Dapsone. Extensive, but uncontrolled experience and two published surveys on the use of Dapsone in pregnant women have not shown that Dapsone increases the risk of fetal abnormalities if administered during all trimesters of pregnancy or can affect reproduction capacity. Because of the lack of animal studies or controlled human experience, Dapsone should be given to a pregnant woman only if clearly needed. In general, for leprosy, USPHS at Carville recommends maintenance of Dapsone. Dapsone has been important for the management of some pregnant D.H. patients.
Pregnancy Category (AUS):
- Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Dapsone in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Dapsone during labor and delivery.
Nursing Mothers
Dapsone is excreted in breast milk in substantial amounts. Hemolytic reactions can occur in neonates. See section on hemolysis. Because of the potential for tumorgenicity shown for Dapsone in animal studies a decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of drug to the mother.
Pediatric Use
Pediatric patients are treated on the same schedule as adults but with correspondingly smaller doses. Dapsone is generally not considered to have an effect on the later growth, development and functional development of the pediatric patient.
Geriatic Use
There is no FDA guidance on the use of Dapsone with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Dapsone with respect to specific gender populations.
Race
There is no FDA guidance on the use of Dapsone with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Dapsone in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Dapsone in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Dapsone in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Dapsone in patients who are immunocompromised.
Administration and Monitoring
Administration
- Oral
Monitoring
There is limited information regarding Monitoring of Dapsone in the drug label.
IV Compatibility
There is limited information regarding IV Compatibility of Dapsone in the drug label.
Overdosage
Nausea, vomiting, hyperexcitability can appear a few minutes up to 24 hours after ingestion of an overdosage. Methemoglobin induced depression, convulsions or severe cyanosis requires prompt treatment. In normal and methemoglobin reductase deficient patients, methylene blue, 1-2 mg/kg of body weight, given slowly intravenously, is the treatment of choice. The effect is complete in 30 minutes, but may have to be repeated if methemoglobin reaccumulates. For non-emergencies, if treatment is needed, methylene blue may be given orally in doses of 3-5 mg/kg every 4-6 hours. Methylene blue reduction depends on G6PD and should not be given to fully expressed G6PD deficient patients.
Pharmacology
Mechanism of Action
The mechanism of action in Dermatitis herpetiformis has not been established. By the kinetic method in mice, Dapsone is bactericidal as well as bacteriostatic against Mycobacterium leprae.
Structure
- Dapsone-USP, 4,4'-diaminodiphenylsulfone (DDS), is a primary treatment for Dermatitis herpetiformis. It is an antibacterial drug for susceptible cases of leprosy. It is a white, odorless crystalline powder, practically in-soluble in water and insoluble in fixed and vegetable oils.
- Dapsone is issued on prescription in tablets of 25 and 100 mg for oral use.
Inactive Ingredients: Colloidal silicone dioxide, magnesium stearate, microcrystalline cellulose and corn starch.
Pharmacodynamics
There is limited information regarding Pharmacodynamics of Dapsone in the drug label.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of Dapsone in the drug label.
Nonclinical Toxicology
Carcinogenesis, mutagenesis: Dapsone has been found carcinogenic (sarcomagenic) for male rats and female mice causing mesenchymal tumors in the spleen and peritoneum, and thyroid carcinoma in female rats. Dapsone is not mutagenic with or without microsomal activation in S. typhimurium tester strains 1535, 1537, 1538, 98, or 100.
Clinical Studies
There is limited information regarding Clinical Studies of Dapsone in the drug label.
How Supplied
- Dapsone Tablets USP, 25 mg are available as round white scored tablets, debossed “25” above and “102” below the score and on the obverse “JACOBUS” in a Unit of Use carton of 30 tablets (2 x 15). The blisters are light and child-resistant. NDC 49938-102-30.
- Dapsone Tablets USP, 100 mg are available as round white scored tablets, debossed “100” above and “101” below the score and on the obverse “JACOBUS” in a Unit of Use carton of 30 tablets (2 x 15).The blisters are light and child-resistant. NDC 49938-101-30.
- Dapsone Tablets USP, 25 mg are available as round white scored tablets, debossed “25” above and “102” below the score and on the obverse “JACOBUS” in a Unit of Use carton of 28 tablets (2 x 14). The blisters are light and child-resistant. NDC 49938-102-28.
- Dapsone Tablets USP, 100 mg are available as round white scored tablets, debossed“100" above and “101” below the score and on the obverse “JACOBUS” in a Unit of Use carton of 28 tablets (2 x 14). The blisters are light and child-resistant. NDC 49938-101-28.
Storage
There is limited information regarding Dapsone (oral) Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Dapsone (oral) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Dapsone (oral) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Patient Counseling Information of Dapsone in the drug label.
Precautions with Alcohol
- Alcohol-Dapsone interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
Dapsone
Look-Alike Drug Names
There is limited information regarding Dapsone (oral) Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
{{#subobject:
|Page Name=Dapsone (oral)
|Pill Name=No image.jpg
|Drug Name=
|Pill Ingred=|+sep=;
|Pill Imprint=
|Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
|Pill Color=|+sep=;
|Pill Shape=
|Pill Size (mm)=
|Pill Scoring=
|Pill Image=
|Drug Author=
|NDC=
}}
{{#subobject:
|Label Page=Dapsone (oral) |Label Name=Dapsone ingredients and appearance.png
}}
{{#subobject:
|Label Page=Dapsone (oral) |Label Name=Dapsone fig01.jpg
}}